BLPH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 13:56):

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States...

Stats
Today's Volume	10 622.00
Average Volume	37 860.00
Market Cap	764 538
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-13	Puissance Capital Management Lp	Sell	1 076 841	Common Stock
2023-06-07	Amin Naseem	Buy	47 578	Common Stock
2023-06-07	Fernandes Peter	Sell	100 000	Stock Options (Right to Buy)
2023-06-07	Shah Parag Suresh	Sell	50 000	Stock Options (Right to Buy)
2023-06-07	Dekker Martin	Sell	50 000	Stock Options (Right to Buy)

INSIDER POWER
-74.29
Last 99 transactions
Buy: 6 532 145 \| Sell: 5 633 542

Bellerophon Therapeutics Correlation

10 Most Positive Correlations
CPTA	0.936
SGEN	0.934
RETA	0.929
NVCT	0.924
XLRN	0.922
DUOL	0.92
FLMN	0.919
LMB	0.919
RELY	0.918
GPACU	0.916

10 Most Negative Correlations
CMLS	-0.959
JRJC	-0.949
AADI	-0.947
CPTN	-0.944
IHRT	-0.942
MDRX	-0.942
MICS	-0.942
EYE	-0.941
ESSA	-0.94
SILK	-0.938

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bellerophon Therapeutics Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.08

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.08

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.870

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.17

Financial Reports:

No articles found.

Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.